The axis of Bcl-2, plasmacytoid DCs and lupus as a basis for therapy

Bcl-2、浆细胞样 DC 和狼疮的轴作为治疗的基础

• 批准号: nhmrc : GNT1105209
• 负责人: Dr Yifan Zhan
• 金额: $ 71.22万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/axis-bcl-2-basis-therapy/1346418
• 关键词: axis; Bcl; plasmacytoid; DCs; lupus

Systemic lupus erythematosus (SLE) affects 1 in 1000 Australians, mostly women. Here the immune system goes awry and makes antibodies against the body’s own components including the body’s DNA. This leads to damage to many parts of the body including kidneys, joints, brain and heart. It is incurable. A particular immune cell controls the development of this disease and we have found this cell is selectively killed by an inexpensive drug, which we hope will be a better way of treating SLE.

系统性红斑狼疮(SLE)影响1000名澳大利亚人中的1人，主要是女性。在这种情况下，免疫系统会出问题，产生针对人体自身成分的抗体，包括人体的DNA。这会导致身体的许多部位受损，包括肾脏、关节、大脑和心脏。这是不治之症。一种特定的免疫细胞控制着这种疾病的发展，我们发现这种细胞可以被一种廉价的药物选择性地杀死，我们希望这将是治疗SLE的更好方法。